<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240821001310&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240821001310&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 21 Aug 2024 04:13:11 +0000</lastbuilddate>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Correction to: An autoantibody profile detects Brugada syndrome and identifies abnormally expressed myocardial proteins</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39163133/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 20:ehae395. doi: 10.1093/eurheartj/ehae395. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39163133/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39163133</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae395>10.1093/eurheartj/ehae395</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39163133</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: An autoantibody profile detects Brugada syndrome and identifies abnormally expressed myocardial proteins</dc:title>
<dc:identifier>pmid:39163133</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae395</dc:identifier>
</item>
<item>
<title>Correction to: Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39163128/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 20:ehae243. doi: 10.1093/eurheartj/ehae243. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39163128/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39163128</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae243>10.1093/eurheartj/ehae243</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39163128</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial</dc:title>
<dc:identifier>pmid:39163128</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae243</dc:identifier>
</item>
<item>
<title>The ESC Working Group on Cellular Biology of the Heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39162572/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 20:ehae017. doi: 10.1093/eurheartj/ehae017. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39162572/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39162572</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae017>10.1093/eurheartj/ehae017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39162572</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Cinzia Perrino</dc:creator>
<dc:creator>Maurizio Pesce</dc:creator>
<dc:creator>Sean M Davidson</dc:creator>
<dc:date>2024-08-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The ESC Working Group on Cellular Biology of the Heart</dc:title>
<dc:identifier>pmid:39162572</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae017</dc:identifier>
</item>
<item>
<title>Triglycerides: the past, the present, and the future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39162355/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 20:ehae515. doi: 10.1093/eurheartj/ehae515. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39162355/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39162355</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae515>10.1093/eurheartj/ehae515</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39162355</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:date>2024-08-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Triglycerides: the past, the present, and the future</dc:title>
<dc:identifier>pmid:39162355</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae515</dc:identifier>
</item>
<item>
<title>Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39162035/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with T2DM and HFpEF, a 2-week oral KE treatment increased cardiac output and reduced cardiac filling pressures and ventricular stiffness. At peak exercise, KE treatment markedly decreased pulmonary capillary wedge pressure and improved pressure-flow relationship. Modulation of circulating ketone levels is a potential new treatment modality for patients with T2DM and HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20. doi: 10.1161/CIRCULATIONAHA.124.069732. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a major cause of morbidity and mortality in patients with type 2 diabetes (T2DM). Acute increases in circulating levels of ketone body 3-hydroxybutyrate have beneficial acute hemodynamic effects in patients without T2DM with chronic heart failure with reduced ejection fraction. However, the cardiovascular effects of prolonged oral ketone ester (KE) treatment in patients with T2DM and HFpEF remain unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 24 patients with T2DM and HFpEF completed a 6-week randomized, double-blind crossover study. All patients received 2 weeks of KE treatment (25 g D-ß-hydroxybutyrate-(R)-1,3-butanediol × 4 daily) and isocaloric and isovolumic placebo, separated by a 2-week washout period. At the end of each treatment period, patients underwent right heart catheterization, echocardiography, and blood samples at trough levels of intervention, and then during a 4-hour resting period after a single dose. A subsequent second dose was administered, followed by an exercise test. The primary end point was cardiac output during the 4-hour rest period.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During the 4-hour resting period, circulating 3-hydroxybutyrate levels were 10-fold higher after KE treatment (1010±56 µmol/L; <i>P</i>&lt;0.001) compared with placebo (91±55 µmol/L). Compared with placebo, KE treatment increased cardiac output by 0.2 L/min (95% CI, 0.1 to 0.3) during the 4-hour period and decreased pulmonary capillary wedge pressure at rest by 1 mm Hg (95% CI, -2 to 0) and at peak exercise by 5 mm Hg (95% CI, -9 to -1). KE treatment decreased the pressure-flow relationship (∆ pulmonary capillary wedge pressure/∆ cardiac output) significantly during exercise (<i>P</i>&lt;0.001) and increased stroke volume by 10 mL (95% CI, 0 to 20) at peak exercise. KE right-shifted the left ventricular end-diastolic pressure-volume relationship, suggestive of reduced left ventricular stiffness and improved compliance. Favorable hemodynamic responses of KE treatment were also observed in patients treated with sodium-glucose transporter-2 inhibitors and glucagon-like peptide-1 analogs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with T2DM and HFpEF, a 2-week oral KE treatment increased cardiac output and reduced cardiac filling pressures and ventricular stiffness. At peak exercise, KE treatment markedly decreased pulmonary capillary wedge pressure and improved pressure-flow relationship. Modulation of circulating ketone levels is a potential new treatment modality for patients with T2DM and HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT05236335.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39162035/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39162035</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069732>10.1161/CIRCULATIONAHA.124.069732</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39162035</guid>
<pubDate>Tue, 20 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Nigopan Gopalasingam</dc:creator>
<dc:creator>Kristoffer Berg-Hansen</dc:creator>
<dc:creator>Kristian Hylleberg Christensen</dc:creator>
<dc:creator>Bertil T Ladefoged</dc:creator>
<dc:creator>Steen Hvitfeldt Poulsen</dc:creator>
<dc:creator>Mads Jønsson Andersen</dc:creator>
<dc:creator>Barry Borlaug</dc:creator>
<dc:creator>Roni Nielsen</dc:creator>
<dc:creator>Niels Møller</dc:creator>
<dc:creator>Henrik Wiggers</dc:creator>
<dc:date>2024-08-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:39162035</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069732</dc:identifier>
</item>
<item>
<title>Correction to: Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159229/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):e197. doi: 10.1161/CIR.0000000000001275. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159229/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39159229</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001275>10.1161/CIR.0000000000001275</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159229</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:39159229</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001275</dc:identifier>
</item>
<item>
<title>Correction to: Past, Present, and Future of CTA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159228/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):e199. doi: 10.1161/CIR.0000000000001283. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159228/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39159228</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001283>10.1161/CIR.0000000000001283</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159228</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Past, Present, and Future of CTA</dc:title>
<dc:identifier>pmid:39159228</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001283</dc:identifier>
</item>
<item>
<title>Correction to: 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159227/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):e198. doi: 10.1161/CIR.0000000000001277. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159227/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39159227</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001277>10.1161/CIR.0000000000001277</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159227</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:39159227</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001277</dc:identifier>
</item>
<item>
<title>Does PPG, the Other Dimension to FFR, Better Predict Post-PCI Results?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159226/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):598-599. doi: 10.1161/CIRCULATIONAHA.124.070439. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159226/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39159226</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070439>10.1161/CIRCULATIONAHA.124.070439</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159226</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Morton J Kern</dc:creator>
<dc:creator>Arnold H Seto</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Does PPG, the Other Dimension to FFR, Better Predict Post-PCI Results?</dc:title>
<dc:identifier>pmid:39159226</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070439</dc:identifier>
</item>
<item>
<title>Congenital Heart Surgery: In Rapid Evolution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159225/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):583-585. doi: 10.1161/CIRCULATIONAHA.124.068655. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159225/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39159225</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068655>10.1161/CIRCULATIONAHA.124.068655</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159225</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Pedro J Del Nido</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Congenital Heart Surgery: In Rapid Evolution</dc:title>
<dc:identifier>pmid:39159225</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068655</dc:identifier>
</item>
<item>
<title>Diagnosis of Brugada Syndrome With a Sodium-Channel-Blocker Test: Who Should Be Tested? Who Should Not?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159224/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>Intravenous infusion of sodium-channel blockers (SCB) with either ajmaline, flecainide, procainamide, or pilsicainide to unmask the ECG of Brugada syndrome is the drug challenge most commonly used for diagnostic purposes when investigating cases possibly related to inherited arrhythmia syndromes. For a patient undergoing an SCB challenge, the impact of a positive result goes well beyond its diagnostic implications. It is, therefore, appropriate to question who should undergo a SCB test to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):642-650. doi: 10.1161/CIRCULATIONAHA.124.069138. Epub 2024 Aug 19.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Intravenous infusion of sodium-channel blockers (SCB) with either ajmaline, flecainide, procainamide, or pilsicainide to unmask the ECG of Brugada syndrome is the drug challenge most commonly used for diagnostic purposes when investigating cases possibly related to inherited arrhythmia syndromes. For a patient undergoing an SCB challenge, the impact of a positive result goes well beyond its diagnostic implications. It is, therefore, appropriate to question who should undergo a SCB test to diagnose or exclude Brugada syndrome and, perhaps more importantly, who should not. We present a critical review of the benefits and drawbacks of the SCB challenge when performed in cardiac arrest survivors, patients presenting with syncope, family members of probands with confirmed Brugada syndrome, and asymptomatic patients with suspicious ECG.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159224/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39159224</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069138>10.1161/CIRCULATIONAHA.124.069138</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159224</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Sami Viskin</dc:creator>
<dc:creator>Ehud Chorin</dc:creator>
<dc:creator>Raphael Rosso</dc:creator>
<dc:creator>Ahmad S Amin</dc:creator>
<dc:creator>Arthur A Wilde</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Diagnosis of Brugada Syndrome With a Sodium-Channel-Blocker Test: Who Should Be Tested? Who Should Not?</dc:title>
<dc:identifier>pmid:39159224</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069138</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159223/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):651-656. doi: 10.1161/CIRCULATIONAHA.124.071487. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159223/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39159223</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071487>10.1161/CIRCULATIONAHA.124.071487</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159223</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:39159223</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071487</dc:identifier>
</item>
<item>
<title>Letter by Zhang et al Regarding Article, "Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159222/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):e181-e182. doi: 10.1161/CIRCULATIONAHA.124.069623. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159222/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39159222</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069623>10.1161/CIRCULATIONAHA.124.069623</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159222</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Zhipeng Zhang</dc:creator>
<dc:creator>Kai Liu</dc:creator>
<dc:creator>Xiaoping Chen</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Zhang et al Regarding Article, "Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program"</dc:title>
<dc:identifier>pmid:39159222</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069623</dc:identifier>
</item>
<item>
<title>Junctophilin-2 Regulates Mitochondrial Metabolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39159221/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 20;150(8):657-660. doi: 10.1161/CIRCULATIONAHA.123.064343. Epub 2024 Aug 19.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39159221/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39159221</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11335313/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">PMC11335313</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064343>10.1161/CIRCULATIONAHA.123.064343</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39159221</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Sasha Z Prisco</dc:creator>
<dc:creator>Lynn M Hartweck</dc:creator>
<dc:creator>Felipe Kazmirczak</dc:creator>
<dc:creator>Jenna B Mendelson</dc:creator>
<dc:creator>Stephanie L Deng</dc:creator>
<dc:creator>Madelyn Blake</dc:creator>
<dc:creator>Satadru K Lahiri</dc:creator>
<dc:creator>Xander H T Wehrens</dc:creator>
<dc:creator>Kurt W Prins</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Junctophilin-2 Regulates Mitochondrial Metabolism</dc:title>
<dc:identifier>pmid:39159221</dc:identifier>
<dc:identifier>pmc:PMC11335313</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064343</dc:identifier>
</item>
<item>
<title>More questions than answers after NOTION-2</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39158500/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 19:ehae527. doi: 10.1093/eurheartj/ehae527. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39158500/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39158500</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae527>10.1093/eurheartj/ehae527</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39158500</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Victor Dayan</dc:creator>
<dc:creator>Sanjay Kaul</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>More questions than answers after NOTION-2</dc:title>
<dc:identifier>pmid:39158500</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae527</dc:identifier>
</item>
<item>
<title>Underpowered trials: redundant or useful as a canary in the coal mine?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39158494/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 19:ehae528. doi: 10.1093/eurheartj/ehae528. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39158494/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39158494</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae528>10.1093/eurheartj/ehae528</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39158494</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Troels Højsgaard Jørgensen</dc:creator>
<dc:creator>Hans Gustav Hørsted Thyregod</dc:creator>
<dc:creator>Ole De Backer</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Underpowered trials: redundant or useful as a canary in the coal mine?</dc:title>
<dc:identifier>pmid:39158494</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae528</dc:identifier>
</item>
<item>
<title>Loop diuretics in cardiovascular disease: friend or foe?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39158480/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 19:ehae483. doi: 10.1093/eurheartj/ehae483. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39158480/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39158480</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae483>10.1093/eurheartj/ehae483</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39158480</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Annika Rosengren</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Loop diuretics in cardiovascular disease: friend or foe?</dc:title>
<dc:identifier>pmid:39158480</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae483</dc:identifier>
</item>
<item>
<title>Multi-stakeholder workshop on reducing population-wide dietary sodium intake in Nigeria</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39158473/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 19:ehae461. doi: 10.1093/eurheartj/ehae461. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39158473/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39158473</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae461>10.1093/eurheartj/ehae461</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39158473</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Chisom Obiezu-Umeh</dc:creator>
<dc:creator>Mark D Huffman</dc:creator>
<dc:creator>Dike Ojji</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Multi-stakeholder workshop on reducing population-wide dietary sodium intake in Nigeria</dc:title>
<dc:identifier>pmid:39158473</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae461</dc:identifier>
</item>
<item>
<title>Artificial intelligence in cardiovascular medicine: clinical applications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39158472/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>Clinical medicine requires the integration of various forms of patient data including demographics, symptom characteristics, electrocardiogram findings, laboratory values, biomarker levels, and imaging studies. Decision-making on the optimal management should be based on a high probability that the envisaged treatment is appropriate, provides benefit, and bears no or little potential harm. To that end, personalized risk-benefit considerations should guide the management of individual patients to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 19:ehae465. doi: 10.1093/eurheartj/ehae465. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Clinical medicine requires the integration of various forms of patient data including demographics, symptom characteristics, electrocardiogram findings, laboratory values, biomarker levels, and imaging studies. Decision-making on the optimal management should be based on a high probability that the envisaged treatment is appropriate, provides benefit, and bears no or little potential harm. To that end, personalized risk-benefit considerations should guide the management of individual patients to achieve optimal results. These basic clinical tasks have become more and more challenging with the massively growing data now available; artificial intelligence and machine learning (AI/ML) can provide assistance for clinicians by obtaining and comprehensively preparing the history of patients, analysing face and voice and other clinical features, by integrating laboratory results, biomarkers, and imaging. Furthermore, AI/ML can provide a comprehensive risk assessment as a basis of optimal acute and chronic care. The clinical usefulness of AI/ML algorithms should be carefully assessed, validated with confirmation datasets before clinical use, and repeatedly re-evaluated as patient phenotypes change. This review provides an overview of the current data revolution that has changed and will continue to change the face of clinical medicine radically, if properly used, to the benefit of physicians and patients alike.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39158472/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39158472</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae465>10.1093/eurheartj/ehae465</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39158472</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Thomas F Lüscher</dc:creator>
<dc:creator>Florian A Wenzl</dc:creator>
<dc:creator>Fabrizio D'Ascenzo</dc:creator>
<dc:creator>Paul A Friedman</dc:creator>
<dc:creator>Charalambos Antoniades</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence in cardiovascular medicine: clinical applications</dc:title>
<dc:identifier>pmid:39158472</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae465</dc:identifier>
</item>
<item>
<title>The European examination in core cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39158467/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 19:ehae453. doi: 10.1093/eurheartj/ehae453. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39158467/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39158467</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae453>10.1093/eurheartj/ehae453</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39158467</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Chris Plummer</dc:creator>
<dc:creator>Susanna Price</dc:creator>
<dc:creator>Lampros Michalis</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The European examination in core cardiology</dc:title>
<dc:identifier>pmid:39158467</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae453</dc:identifier>
</item>
<item>
<title>Antisense Oligonucleotide Therapy for Calmodulinopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39155863/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240821001310&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These results provide proof of concept that ASOs targeting individual calmodulin genes are potentially effective and safe therapies for calmodulinopathies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 19. doi: 10.1161/CIRCULATIONAHA.123.068111. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Calmodulinopathies are rare inherited arrhythmia syndromes caused by dominant heterozygous variants in <i>CALM1</i>, <i>CALM2</i>, or <i>CALM3</i>, which each encode the identical CaM (calmodulin) protein. We hypothesized that antisense oligonucleotide (ASO)-mediated depletion of an affected calmodulin gene would ameliorate disease manifestations, whereas the other 2 calmodulin genes would preserve CaM level and function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We tested this hypothesis using human induced pluripotent stem cell-derived cardiomyocyte and mouse models of <i>CALM1</i> pathogenic variants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Human <i>CALM1</i><sup><i>F142L/+</i></sup> induced pluripotent stem cell-derived cardiomyocytes exhibited prolonged action potentials, modeling congenital long QT syndrome. CALM1 knockout or CALM1-depleting ASOs did not alter CaM protein level and normalized repolarization duration of <i>CALM1</i><sup><i>F142L/+</i></sup> induced pluripotent stem cell-derived cardiomyocytes. Similarly, an ASO targeting murine <i>Calm1</i> depleted <i>Calm1</i> transcript without affecting CaM protein level. This ASO alleviated drug-induced bidirectional ventricular tachycardia in <i>Calm</i><sup><i>N98S/+</i></sup> mice without a deleterious effect on cardiac electrical or contractile function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These results provide proof of concept that ASOs targeting individual calmodulin genes are potentially effective and safe therapies for calmodulinopathies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39155863/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240821001310&v=2.18.0.post9+e462414">39155863</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068111>10.1161/CIRCULATIONAHA.123.068111</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39155863</guid>
<pubDate>Mon, 19 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Raul H Bortolin</dc:creator>
<dc:creator>Farina Nawar</dc:creator>
<dc:creator>Chaehyoung Park</dc:creator>
<dc:creator>Michael A Trembley</dc:creator>
<dc:creator>Maksymilian Prondzynski</dc:creator>
<dc:creator>Mason E Sweat</dc:creator>
<dc:creator>Peizhe Wang</dc:creator>
<dc:creator>Jiehui Chen</dc:creator>
<dc:creator>Fujian Lu</dc:creator>
<dc:creator>Carter Liou</dc:creator>
<dc:creator>Paul Berkson</dc:creator>
<dc:creator>Erin M Keating</dc:creator>
<dc:creator>Daisuke Yoshinaga</dc:creator>
<dc:creator>Nikoleta Pavlaki</dc:creator>
<dc:creator>Thomas Samenuk</dc:creator>
<dc:creator>Cecilia B Cavazzoni</dc:creator>
<dc:creator>Peter T Sage</dc:creator>
<dc:creator>Qing Ma</dc:creator>
<dc:creator>Robert D Whitehill</dc:creator>
<dc:creator>Dominic J Abrams</dc:creator>
<dc:creator>Chrystalle K Carreon</dc:creator>
<dc:creator>Juan Putra</dc:creator>
<dc:creator>Sanda Alexandrescu</dc:creator>
<dc:creator>Shuai Guo</dc:creator>
<dc:creator>Wen-Chin Tsai</dc:creator>
<dc:creator>Michael Rubart</dc:creator>
<dc:creator>Dieter Kubli</dc:creator>
<dc:creator>Adam E Mullick</dc:creator>
<dc:creator>Vassilios J Bezzerides</dc:creator>
<dc:creator>William T Pu</dc:creator>
<dc:date>2024-08-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Antisense Oligonucleotide Therapy for Calmodulinopathy</dc:title>
<dc:identifier>pmid:39155863</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068111</dc:identifier>
</item>





























</channel>
</rss>